Who is sponsoring NCT01185821?

NCT01185821 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT01185821?

Interventions in NCT01185821: BAF312.

What condition does NCT01185821 study?

NCT01185821 studies Relapsing Remitting Multiple Sclerosis.

Is NCT01185821 still recruiting?

NCT01185821 is currently completed. Last updated 27 March 2018.

Are results published for NCT01185821?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-03-27 · How we verify

NCT01185821

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Completed Phase 2 Results posted Last updated 27 March 2018

What this trial tests

Phase 2 trial testing BAF312 in Relapsing Remitting Multiple Sclerosis in 185 participants. Completed in 10 October 2016.

Timeline

30 August 2010

Primary endpoint
10 October 2016

10 October 2016

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	185
Start date	30 August 2010
Primary completion	10 October 2016
Estimated completion	10 October 2016
Sites	46 locations across Italy, Finland, Russia, Germany, Hungary, Norway, Poland, Canada

Drugs / interventions tested

BAF312 — full drug profile →

Conditions studied

Relapsing Remitting Multiple Sclerosis — all drugs for Relapsing Remitting Multiple Sclerosis →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 56, any sex, with Relapsing Remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study. Primary · Baseline up to approximately 5 years

Refer to adverse events for complete listing of serious adverse events and other adverse events. Adverse events of interest were presented in separate tables. There were no reports of macular edema.

Serious adverse events

Group	Value	95% CI
BAF312 10 mg/2 mg	4
BAF312 2 mg/2 mg	7
BAF312 1.25 mg/2 mg	6
BAF312 .5 mg/2 mg	6
BAF312 .25 mg/2 mg	8

Other adverse events

Group	Value	95% CI
BAF312 10 mg/2 mg	30
BAF312 2 mg/2 mg	26
BAF312 1.25 mg/2 mg	42
BAF312 .5 mg/2 mg	29
BAF312 .25 mg/2 mg	42

Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout) Primary · Baseline Extension up to day 10

Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for \>7 days. Abbreviation: Con=conduction, IVCD=intraventricular conduction defect , WPW=Wolff-Parkinson-White syndrome

Conduction-Prolonged QTc

Group	Value	95% CI
BAF312 10 mg/2 mg	5
BAF312 2 mg/2 mg	2
BAF312 1.25 mg/2 mg	5
BAF312 .5 mg/2 mg	2
BAF312 .25 mg/2 mg	4

Conduction - IVCD

Group	Value	95% CI
BAF312 10 mg/2 mg	3
BAF312 2 mg/2 mg	8
BAF312 1.25 mg/2 mg	1
BAF312 .5 mg/2 mg	3
BAF312 .25 mg/2 mg	0

Conduction - AV Mobitz I

Group	Value	95% CI
BAF312 10 mg/2 mg	1
BAF312 2 mg/2 mg	0
BAF312 1.25 mg/2 mg	0
BAF312 .5 mg/2 mg	0
BAF312 .25 mg/2 mg	0

Con:1st degree AV block

Group	Value	95% CI
BAF312 10 mg/2 mg	0
BAF312 2 mg/2 mg	1
BAF312 1.25 mg/2 mg	1
BAF312 .5 mg/2 mg	1
BAF312 .25 mg/2 mg	1

Conduction - WPW

Group	Value	95% CI
BAF312 10 mg/2 mg	0
BAF312 2 mg/2 mg	0
BAF312 1.25 mg/2 mg	0
BAF312 .5 mg/2 mg	1
BAF312 .25 mg/2 mg	0

Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout) Primary · Baseline Extension up to day 10

Group	Value	95% CI
BAF312 .25 mg/2 mg	4

Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set) Primary · Baseline Extension up to approximately 5 years

Sitting blood pressure was measured in triplicate. The categories of notably low and high values and changes are presented for systolic (SBP) and diastolic (DBP). Multiple occurrences for a patient are counted as one occurrence in this table.

SBP Low: ≤ 90

Group	Value	95% CI
BAF312 10 mg/2 mg	1
BAF312 2 mg/2 mg	3
BAF312 1.25 mg/2 mg	2
BAF312 .5 mg/2 mg	1
BAF312 .25 mg/2 mg	1

SBP ≥ 20 decrease from baseline

Group	Value	95% CI
BAF312 10 mg/2 mg	8
BAF312 2 mg/2 mg	10
BAF312 1.25 mg/2 mg	4
BAF312 .5 mg/2 mg	6
BAF312 .25 mg/2 mg	10

SBP High: ≥ 160

Group	Value	95% CI
BAF312 10 mg/2 mg	1
BAF312 2 mg/2 mg	1
BAF312 1.25 mg/2 mg	1
BAF312 .5 mg/2 mg	3
BAF312 .25 mg/2 mg	3

SBP ≥ 20 increase from baseline

Group	Value	95% CI
BAF312 10 mg/2 mg	9
BAF312 2 mg/2 mg	8
BAF312 1.25 mg/2 mg	12
BAF312 .5 mg/2 mg	13
BAF312 .25 mg/2 mg	18

DBP Low: ≤ 50

Group	Value	95% CI
BAF312 10 mg/2 mg	1
BAF312 2 mg/2 mg	0
BAF312 1.25 mg/2 mg	1
BAF312 .5 mg/2 mg	0
BAF312 .25 mg/2 mg	1

DBP ≥ 15 decrease from baseline

Group	Value	95% CI
BAF312 10 mg/2 mg	14
BAF312 2 mg/2 mg	8
BAF312 1.25 mg/2 mg	10
BAF312 .5 mg/2 mg	10
BAF312 .25 mg/2 mg	10

DBP High: ≥ 100

Group	Value	95% CI
BAF312 10 mg/2 mg	4
BAF312 2 mg/2 mg	7
BAF312 1.25 mg/2 mg	4
BAF312 .5 mg/2 mg	4
BAF312 .25 mg/2 mg	4

DBP ≥ 15 increase from baseline

Group	Value	95% CI
BAF312 10 mg/2 mg	9
BAF312 2 mg/2 mg	13
BAF312 1.25 mg/2 mg	13
BAF312 .5 mg/2 mg	11
BAF312 .25 mg/2 mg	17

Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set) Primary · Baseline Extension up to approximately 5 years

Most infections were clinical diagnoses and were not confirmed by microbiology / virologic investigations. A patient with multiple occurrences of an infection for a preferred term is counted only once in each specific category. Events identified as infections by the Investigator and defined as an AE with onset on or after the first dose of Extension Study drug up to and including 30 days after the date of the last dose

Oral herpes

Group	Value	95% CI
BAF312 10 mg/2 mg	5
BAF312 2 mg/2 mg	0
BAF312 1.25 mg/2 mg	4
BAF312 .5 mg/2 mg	2
BAF312 .25 mg/2 mg	4

Herpes zoster

Group	Value	95% CI
BAF312 10 mg/2 mg	5
BAF312 2 mg/2 mg	0
BAF312 1.25 mg/2 mg	3
BAF312 .5 mg/2 mg	2
BAF312 .25 mg/2 mg	0

Influenza

Group	Value	95% CI
BAF312 10 mg/2 mg	3
BAF312 2 mg/2 mg	4
BAF312 1.25 mg/2 mg	3
BAF312 .5 mg/2 mg	6
BAF312 .25 mg/2 mg	6

Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set) Primary · Baseline Extension up to approximately 5 years

Group	Value	95% CI
BAF312 10 mg/2 mg	1
BAF312 2 mg/2 mg	0
BAF312 1.25 mg/2 mg	1
BAF312 .5 mg/2 mg	0
BAF312 .25 mg/2 mg	1

Number of Relapses in One Year - Annualized Relapse Rates for Overall Extension Study (ARR) (Extension Set) Secondary · Baseline extension up to approximately 5 years

Group level ARR (raw) is calculated as the total number of relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate. Model estimates are based on a negative binomial regression model, adjusted for treatment group, age, baseline EDSS, baseline number of Gd-enhanced T1 lesions and number of relapses in previous 2 years as covariates, with log(time on study in years) as the offset variable, using the log link.

Group	Value	95% CI
BAF312 10 mg/2 mg	0.18	0.11 – 0.31
BAF312 2 mg/2 mg	0.15	0.08 – 0.26
BAF312 1.25 mg/2 mg	0.16	0.10 – 0.26
BAF312 .5 mg/2 mg	0.19	0.11 – 0.33
BAF312 .25 mg/2 mg	0.22	0.14 – 0.35

Percentage of Participants Free of Magnetic Resonance Imaging (MRI) Identified Disease Activity at Any Scan During Extension Study (Extension Set) Secondary · Baseline Extension up to approximately 5 years

Free of MRI disease activity is defined as free of Gadolinium enhanced T1 lesions at any scan; free of new or enlarging T2 lesions at any scan: free of both gadolinium enhanced T1 lesions and new or enlarging T2 lesions at any scan. Number of patients analyzed = patients with at least one MRI scan during the specified time period. New lesions at a specific visit are assessed relative to the previous scheduled visit scan. No imputation of missing scans is performed. As a result missing scans can lead to an overestimation of the proportion of patients free of a specific MRI activity.

Free of Gd-enhanced T1 lesions at any scan

Group	Value	95% CI
BAF312 10 mg/2 mg	58.1
BAF312 2 mg/2 mg	57.7
BAF312 1.25 mg/2 mg	58.1
BAF312 .5 mg/2 mg	44.8
BAF312 .25 mg/2 mg	66.0

Free of new/enlarging T2 lesions at any scan

Group	Value	95% CI
BAF312 10 mg/2 mg	32.3
BAF312 2 mg/2 mg	42.3
BAF312 1.25 mg/2 mg	46.5
BAF312 .5 mg/2 mg	20.7
BAF312 .25 mg/2 mg	40.4

Free of Gd-enhanced T1 and new enlarged T2 lesions

Group	Value	95% CI
BAF312 10 mg/2 mg	32.3
BAF312 2 mg/2 mg	42.3
BAF312 1.25 mg/2 mg	44.2
BAF312 .5 mg/2 mg	20.7
BAF312 .25 mg/2 mg	40.4

Percentage of Participants Free of Confirmed Disability Progression in Extension Study (Extension Set) Secondary · Baseline Extension up to approximately 5 years

Six-month disability progression was defined relative to extension baseline EDSS score: 1.5 point increase in patients with baseline EDSS score of 0, 1.0 increase in patients with baseline EDSS score of between 0.5 to 5.0, inclusive and 0.5 increase in patients with baseline EDSS score of ≥ 5.5. The criteria for 6-month disability progression included detection of onset of progression and confirmation of progression for a period of at least 6 months.

Group	Value	95% CI
BAF312 10 mg/2 mg	72.3	56.0 – 88.7
BAF312 2 mg/2 mg	82.4	66.6 – 98.3
BAF312 1.25 mg/2 mg	84.8	73.5 – 96.0
BAF312 .5 mg/2 mg	81.4	66.6 – 96.1
BAF312 .25 mg/2 mg	78.6	65.4 – 91.9

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse Events (AEs) are collected from First Patient First Visit (FPFV)until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Reporting threshold: 3.999%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

BAF312 10/2 mg

Serious: 4/33 (12%)

Deaths: —

BAF312 2/2 mg

Serious: 7/29 (24%)

Deaths: —

BAF312 1.25/2 mg

Serious: 6/43 (14%)

Deaths: —

BAF312 0.5/2 mg

Serious: 6/29 (21%)

Deaths: —

BAF312 0.25/2 mg

Serious: 8/50 (16%)

Deaths: —

All Patients

Serious: 31/184 (17%)

Deaths: —

Serious adverse events (40 terms)

Reaction	System	BAF312 10/2 mg	BAF312 2/2 mg	BAF312 1.25/2 mg	BAF312 0.5/2 mg	BAF312 0.25/2 mg	All Patients
Multiple sclerosis relapse	Nervous system disorders	—	—	—	—	—	—
Basal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Breast cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Splenic cyst	Blood and lymphatic system disorders	—	—	—	—	—	—
Otosclerosis	Ear and labyrinth disorders	—	—	—	—	—	—
Glaucoma	Eye disorders	—	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—	—
Gastritis	Gastrointestinal disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Pancreatitis acute	Gastrointestinal disorders	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Submandibular mass	General disorders	—	—	—	—	—	—
Biliary dyskinesia	Hepatobiliary disorders	—	—	—	—	—	—
Anaphylactic reaction	Immune system disorders	—	—	—	—	—	—
Oral herpes	Infections and infestations	—	—	—	—	—	—
Pyelonephritis	Infections and infestations	—	—	—	—	—	—
Pyelonephritis acute	Infections and infestations	—	—	—	—	—	—
Respiratory tract infection	Infections and infestations	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—
Ankle fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—
Craniocerebral injury	Injury, poisoning and procedural complications	—	—	—	—	—	—
Femur fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—
Tendon rupture	Injury, poisoning and procedural complications	—	—	—	—	—	—
Smear cervix abnormal	Investigations	—	—	—	—	—	—

Other adverse events (125 terms — click to expand)

Reaction	System	BAF312 10/2 mg	BAF312 2/2 mg	BAF312 1.25/2 mg	BAF312 0.5/2 mg	BAF312 0.25/2 mg	All Patients
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—
Lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—	—	—
Melanocytic naevus	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Depression	Psychiatric disorders	—	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Oral herpes	Infections and infestations	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—
Lymphocyte count decreased	Investigations	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—
Hypercholesterolaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—
Herpes zoster	Infections and infestations	—	—	—	—	—	—
Tonsillitis	Infections and infestations	—	—	—	—	—	—
Skin papilloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—	—
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Paraesthesia	Nervous system disorders	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Cystitis	Infections and infestations	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—

Most-reported serious reactions: Multiple sclerosis relapse, Basal cell carcinoma, Breast cancer, Splenic cyst, Otosclerosis, Glaucoma, Abdominal discomfort, Gastritis.

Data from ClinicalTrials.gov NCT01185821 adverse events section.

Sponsor's own description

This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Sphingosine 1-phosphate: Lipid signaling in pathology and therapy.
Cartier A, Hla T. · · 2019 · cited 477× · PMID 31624181 · DOI 10.1126/science.aar5551
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.
Kunkel GT, Maceyka M, Milstien S, Spiegel S. · · 2013 · cited 377× · PMID 23954895 · DOI 10.1038/nrd4099
Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery.
Park SJ, Im DS. · · 2017 · cited 103× · PMID 28035084 · DOI 10.4062/biomolther.2016.160
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Chaudhry BZ, Cohen JA, Conway DS. · · 2017 · cited 99× · PMID 28812220 · DOI 10.1007/s13311-017-0565-4
Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis Than Victim in Neurological Disorders.
Xiao M, Xiao ZJ, Yang B, Lan Z, et al · · 2020 · cited 87× · PMID 32903669 · DOI 10.3389/fnins.2020.00764
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
Kappos L, Li DK, Stüve O, Hartung HP, et al · · 2016 · cited 79× · PMID 27380540 · DOI 10.1001/jamaneurol.2016.1451
The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.
Lucaciu A, Brunkhorst R, Pfeilschifter JM, Pfeilschifter W, et al · · 2020 · cited 53× · PMID 32580348 · DOI 10.3390/cells9061515
Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
Kihara Y, Chun J. · · 2023 · cited 13× · PMID 37149155 · DOI 10.1016/j.pharmthera.2023.108432

Verify or expand the search:

Other trials of BAF312

Trials testing the same drug.

NCT04792567 — Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (A · Phase 4 · completed
NCT02029274 — Safety and Efficacy of BAF312 in Dermatomyositis · Phase 2 · terminated
NCT01801917 — Efficacy and Tolerability of BAF312 in Patients With Polymyositis · Phase 2 · terminated
NCT01665144 — Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) · Phase 3 · completed
NCT01148810 — Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis · Phase 2 · terminated

Other recruiting trials for Relapsing Remitting Multiple Sclerosis

Currently open trials in the same condition.

NCT06796504 — The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study · NA · recruiting
NCT05949580 — Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple · recruiting
NCT06282081 — Serum Neurofilament Light in Multiple Sclerosis · active not recruiting
NCT05327322 — Functional Outcomes From Diets in Multiple Sclerosis · NA · active not recruiting
NCT05171972 — Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment · active not recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01185821 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 27 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01185821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01185821

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (40 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of BAF312

Other recruiting trials for Relapsing Remitting Multiple Sclerosis

Other Novartis Pharmaceuticals trials

Verify against primary sources